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Breast cancer (BC) survival rates in sub-Saharan Africa (SSA) are low in part due to advanced stage at diagnosis. As one com-
ponent of a study of the entire journey of SSA women with BC, we aimed to identify shared and setting-specific drivers of
advanced stage BC. Women newly diagnosed in the multicountry African Breast Cancer–Disparities in Outcomes (ABC-DO)
study completed a baseline interview and their stage information was extracted from medical records. Ordinal logistic regres-
sion was used to estimate odds ratios (OR) and 95% confidence intervals (CI) for advanced stage (I, II, III, IV) in relation to
individual woman-level, referral and biological factors. A total of 1795 women were included from Nigeria, Uganda, Zambia,
and the multiracial populations of Namibia and South Africa, 1091 of whom (61%) were stage III/IV. Stage was lower in
women with greater BC knowledge (OR 0.77 (95% CI: 0.70, 0.85) per point on a 6 point scale). More advanced stage was
associated with being black (4.00 (2.79, 5.74)), having attended <secondary education (1.75 (1.42, 2.16)), having never heard
of BC (1.64 (1.31, 2.06)), an unskilled job (1.77 (1.43, 2.20)) and pregnancy in the past 3 years (30% of 45 year olds) (1.63
(1.15, 2.31)), and were mediated through delays to diagnosis: symptom duration of 1 year (OR 2.47 (1.93, 3.15)). These
findings provide further evidence that late-stage BC in SSA is largely attributed to modifiable factors and strategies to improve
BC education and awareness in women and the health system should be intensified.
Breast cancer (BC) is the most common cancer and the sec-
ond most common cause of cancer death in women in sub-
Saharan Africa (SSA).1 In high-income countries, this cancer
generally has a favorable prognosis, but unfortunately this is
not the case in SSA. The few published ﬁve-year survival esti-
mates are close to, or below, 50%,2–7 and stand in marked
contrast to 80% and 91% for US black and white women,
respectively, diagnosed 2005–2011.8 The reasons for poor
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survival in SSA are multifactorial, involving late presentation
and stage at diagnosis, barriers to receiving and complying
with appropriate treatment, and possibly, differences in
tumor biology. Stage at diagnosis is a key prognostic factor
for BC universally, including in SSA.4,9 For example, in Ethi-
opia in 2005–10, 5-year distant metastases-free survival was
72% for stage I/II compared with 33% for stage III.9
As one of the multiple strategies needed to reduce BC
deaths, the Breast Health Global Initiative (BHGI) recom-
mends that the prevention of advanced symptomatic BC,
using resource-appropriate strategies, should be regarded as a
priority in low-income settings.10 This priority is pertinent to
SSA, where a recent systematic review revealed that between
45% and 90% of women are diagnosed at stage III and IV in
different settings, none of which have organized screening
programs.11 This wide range of advanced stage tumors sug-
gests that BC stage migration may be a realistic target within
similarly resource-limited settings, for which an understand-
ing of context-speciﬁc drivers of advanced stage at diagnosis
is ﬁrst needed.
Advanced stage at diagnosis is a function of a combina-
tion of the rate of tumor growth or spread, and the actions
or reactions leading to the timing of diagnosis. The rate of
tumor growth can be affected by biological determinants
such as hormone receptor and/or environmental factors such
hormone exposure during pregnancy. The likelihood of meta-
static spread increases as cancers grow, meaning that delays
to prompt diagnosis and treatment are associated with wors-
ened prognosis, delays that can be attributed to both system-
and woman-level (lifestyle, sociodemographic) factors.12 In
SSA, BC diagnosis typically concerns symptomatic disease,
therefore the time interval between onset of symptoms and
seeking help provides a critical time window of opportunity
for achieving early diagnosis.13,14 To react and seek help,
however, patients must go through “symptom appraisal,”14 a
process which is likely to be heavily inﬂuenced by a woman’s
awareness of BC, and by the unique socio-cultural character-
istics and belief systems prevalent in the SSA region.
The African Breast Cancer – Disparities in Outcomes
(ABC-DO) study is a multicountry prospective study of BC
outcomes in SSA. Among this BC cohort, we aimed to iden-
tify major shared and setting-speciﬁc drivers of advanced
stage at BC diagnosis, including woman-level, referral-related
and symptom duration and biological-level factors. We fur-
ther attempted to examine whether the identiﬁed drivers
operated mainly through changes in the rate of tumor growth
or through time delays in BC diagnosis.
Methods
Study design and participants
ABC-DO is a prospective hospital-based study of outcomes
after new BC diagnosis in adult (18 years old) women in
ﬁve SSA countries, as described in detail previously.15 The
present analysis concerns 1939 women primarily recruited
in tertiary hospitals: Windhoek Central Hospital, Namibia;
Mulago Hospital and the Uganda Cancer Institute, Kam-
pala, Uganda; the Federal Medical Centre, Owerri, Nigeria;
University Teaching Hospital and the Cancer Diseases Hos-
pital, Lusaka, Zambia; and the Chris Hani Baragwanath
Academic Hospital, Soweto, South Africa (SA). In Aba,
Nigeria, patients originated from Abia State University
Teaching Hospital and the Maranatha private clinic hospital.
The latter comprised a different patient proﬁle and route to
diagnosis than the other settings, and thus was considered
as a distinct setting from the other Nigerian hospitals.
Within the Nigerian healthcare system, private hospitals are
utilized more than public, and waiting time is reported as
the strongest determinant of facility choice,16,17 meaning, in
contrast to many other settings, private clinics are not
restricted to the very rich and can have over representation
of palliative care patients.
Recruitment started in September–December 2014, and
had completed by April 2017, with the exception of Zambia
(May 2016–September 2017), and SA which is ongoing for
other purposes. For SA, women diagnosed until the last data
extract (22 November 2016) were included. Participation
involved a baseline interview, consent to access medical
records and tumor tissue, and to be actively followed up tele-
phonically at regular intervals.
ABC-DO was approved by ethics committees of all
involved institutions: IARC (IEC 13–19, IEC15–18), LSHTM
(6459), Federal Medical Centre Owerri, Abia State University
Teaching Hospital, University of Zambia Biomedical Research
Ethics Committee (004–08–15), University of Witwatersrand
(M150345), Uganda National Council for Science and Tech-
nology (HS 1588) and the Ministry of Health and Social
Services of Namibia (17/3/3).
Baseline questionnaire
The same face-to-face baseline questionnaire was utilized in
all settings except SA where a pre-existing one was adminis-
tered and harmonized to ABC-DO as outlined below. For the
current analysis we included questions on age, marital and
menopausal status at diagnosis (deﬁned in Table 1 footnotes);
What’s new?
Breast cancer (BC) patients in sub-Saharan Africa (SSA) tend to have poor prognoses and low survival rates. This is largely
because the majority of cases are not diagnosed until the disease has reached an advanced stage. In this study, the authors
found that delayed diagnosis is associated with several modifiable factors, including limited schooling, low-wage jobs, and
lack of awareness of BC. With incidence rates of BC steadily climbing in SSA, it is urgent that efforts to improve disease-
specific education and awareness both among women and throughout the healthcare system be intensified.
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Table 1. Women and breast tumor characteristics in the ABC-DO cohort, overall and by stage at diagnosis1
Variable Category or unit Total (n51795) Lower stage (0,I,II)6 Advanced stage (III,IV)7
Column % N N Row %
All women - 100 704 1091 61
Country and ethnic group Namibia – black 22 143 256 64
Namibia – non-black 6 78 26 25
Nigeria – public 17 88 211 71
Nigeria – private clinic 4 11 61 85
South Africa – black 19 164 186 53
South Africa – non-black 2 21 9 30
Uganda 22 143 256 64
Zambia 8 56 86 61
Age at diagnosis, years Mean (SD) 53 (14) 50 (14)
Woman-level
Married Yes 46 317 797 61
No 54 384 588 60
Received secondary education Yes 58 443 568 56
No 42 230 488 68
Employment (current/past) Skilled 28 243 258 52
Unskilled 49 281 581 67
N/A 23 170 243 59
SEP score Low (0–3) 33 189 403 68
Medium (4–6) 36 213 420 66
High (7–9) 31 291 254 47
Parous Yes 92 633 978 61
No 8 57 89 61
Ever heard of BC yes 81 608 838 58
no 19 88 247 74
BC knowledge score Low (0–2) 14 80 160 67
Medium (3) 41 261 477 65
High (4–5) 45 355 448 56
missing 8 6 43
Referral-level
Contacts with providers 1 13 73 144 66
2 22 152 228 60
3 27 186 275 60
4 18 131 184 58
51 20 129 224 63
Resides in urban area Yes 53 395 547 58
No 47 309 543 64
Symptom duration (months) <3 29 261 231 47
3 to <6 18 123 184 60
6 to <12 20 112 222 66
121 33 167 400 71
Biological-level
HIV positive Yes 10 62 116 65
No/nk 90 642 975 60
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detailed self-identiﬁed ethnic group was ascertained and
dichotomized as black versus non-black. Employment was
grouped into 3 categories: highly skilled/skilled, unskilled,
and not applicable in ABC-DO and, respectively, employed,
unemployed and retired in SA. Usual place of residence was
deﬁned as urban (city/town) or rural (village/rural) in ABC-
DO and, in SA, as residing <10 km or 10 km straight-line
distance to the diagnostic hospital. A score for socioeconomic
position (SEP) ranging from 0 (low) to 9 (high) was gener-
ated from the sum of 9 equally-weighted (11 each) posses-
sions and facilities: home ownership; indoor water; ﬂush
toilet; electricity; vehicle; refrigerator; landline phone; gas or
electric stove; and a bed. HIV infection (yes vs. no/not
known) was based on self-reports (97% agreement with clini-
cal records among those for whom the latter were available).
Having other comorbidities (yes vs no) included any one of
high blood pressure (the most common), heart disease, diabe-
tes and history of any cancer and in all countries except
SA it additionally included anemia, chronic obstructive
pulmonary diseases, asthma, hepatitis, tuberculosis, other
infections, and any other diseases. Measurements of height
and weight at recruitment were used to calculate body mass
index (BMI, kg/m2), which was categorized into standard
WHO groupings.18 An indicator for recent pregnancy (yes vs
no), deﬁned as being pregnant at diagnosis or having given
birth within 3 years of diagnosis, was created for all sites
except SA where this information was not collected.
BC awareness prior to the current diagnosis was assessed
at all sites. Indicators included whether the woman had ever
heard of BC (yes vs no/do not know) and, in all sites except
SA, whether BC is curable (yes vs no/do not know). A BC
knowledge score (range 0–5 (highest)) was generated from
the sum of positive answers (11 each) to: (i) ever knowing
anyone with BC; (ii) believing BC can be inherited; and nega-
tive responses (11) to: believing BC could be (iii) caught
from others; caused by (iv) an injury to the breast or (v) a
curse or spiritual attack. Women were also asked to recall
their journey to BC diagnosis. Two key features of this
Table 1. Women and breast tumor characteristics in the ABC-DO cohort, overall and by stage at diagnosis (Continued)
Variable Category or unit Total (n51795) Lower stage (0,I,II)6 Advanced stage (III,IV)7
Column % N N Row %
Receiving antiretrovirals2 Yes 89 39 78 67
Any other comorbidity - 50 361 534 60
BMI, kg/m2 Mean (SD) 28 (7) 27 (6)
Post-menopausal at diagnosis3 Yes 53 397 548 58
No 47 307 543 64
Recent pregnancy4 Yes 12 41 128 76
No 88 478 768 62
Tumor size (mm) Median (IQR) 35 (22–50) 70 (42–100)
Grade Well differentiated 11 81 115 59
Moderately 29 232 280 55
Poorly 21 154 230 60
Unknown 39 237 466 66
Morphology5 Ductal 79 520 774 60
Receptor status ER/PR1 HER22 57 248 287 54
ER/PR1 HER21 19 86 98 53
ER-PR-HER21 7 29 40 58
Triple negative 17 57 100 64
Missing 284 566 67
1% lower/advanced amongst non-missing data. Missing data were few: marital status (n5 9), education (n5 66), employment (n5 19), SEP
(n5 25), BC awareness (n514); BMI (n5 108); contacts with health providers (n569); delay time (n595); comorbidity (n57); morphology
(n5 153); parity (n5 38).
2Among those listed HIV1 on medical records.
3Postmenopausal women had no menstrual periods in the previous 6 months, or had irregular periods or missing status and were over age 50; pre-
menopausal had regular periods, or irregular/missing periods information and were under age 50 (median age at menopause within ABCDO was 49
years).
4Information not available for South Africa—% from Namibia, Nigeria, Uganda and Zambia.
5348 of which are lobular or other.
6Stage 0, I, IIA and IIB have 22, 102, 282 and 298 women, respectively.
7Stage IIIA, IIIB, IIIC and IV had 302, 415, 96 and 278 women, respectively. Metastatic site: bone (n5 27), liver (88), lung (62), brain (12), not
specified (48).
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journey were included in the present analysis: (i) the total
number of pre-diagnostic contacts with health care providers,
including traditional and alternative care providers, and (ii)
symptom duration, as self-recalled from the date when the
woman noticed the ﬁrst symptom/sec to the date of BC diag-
nosis, with the later deﬁned as per the European Network of
Cancer Registries guidelines19 and which typically coincided
with the date of interview.
Stage at diagnosis and other tumor characteristics
BC stage at diagnosis, prior to the initiation of any treatment,
was assessed using the American Joint Committee on Cancer
(AJCC) TNM staging system.20 Clinical staging and ultra-
sound were the primary methods used to ascertain stage,
with <5% assessed using magnetic resonance imaging, com-
puterized tomography or bone scan. Information on stage
was available for 93% (n5 1795) of women overall; <1% was
missing in Namibia, 1% in SA, 14% in Nigeria, 9% in
Uganda, and 19% in Zambia due to ongoing data collection.
Strike action that prohibited access to medical records led to
higher proportions of missing stage information in Nigeria
but likely in an unbiased fashion. Other tumor characteristics
obtained were grade and morphology. Additionally, in SA
and Namibia and occasionally at other sites, receptor status
was determined (oestrogen-receptor (ER), progesterone-
receptor (PR) and human epidermal growth factor receptor 2
(HER2)), by immunohistochemistry and, for HER2, ﬂores-
cent in situ hybridization. ER and PR were considered posi-
tive if >1% staining was present, and HER2 as positive if
FISH was positive or HER2 score was 3.
Pathways to advanced stage at diagnosis
In an attempt to assess whether identiﬁed drivers of
advanced stage at diagnosis were likely to act mainly through
a time-to-diagnosis pathway or a tumor progression rate
pathway, neither of which could be directly observed, the
modeling strategy considered a priori confounders as core
factors (age, ethnicity and country setting) and assumed that
the total time-to-diagnosis, which is the sum of time from
symptom onset to symptom recognition (unobserved) and
symptom duration, is affected by determinants of the actions
and reactions at the woman-level (marital status and family,
education, employment and BC awareness) and by referral fac-
tors (contacts with health care providers, residential setting).12
The modeling strategy also assumed that tumor growth rate is
affected by biological factors (tumor subtype, grade and mor-
phology, BMI, HIV and comorbidities, menopausal status, and
recent pregnancy as such tumors tend to be more aggressive
due to the pregnancy hormonal milieu).21–23
Statistical methods
The primary outcome was stage at diagnosis, which was ana-
lyzed using ordinal logistic regression models to estimate
odds ratios (OR) for more advanced tumor stage, coded into
4 levels, 1 through 4, for stages 15 0 & I; 25 IIA & IIB;
35 IIIA, IIIB, & IIIC; 45 stage IV. This model assumes a
common OR for each ordered dichotomy of the 4 stages.
ORs were ﬁrst examined separately in relation to three
groups of factors: woman-level, referral and biological factors
(as deﬁned above). For each, ORs were ﬁrst estimated adjust-
ing for age at diagnosis (categorical), country setting, and
black/non-black ethnicity (“core models”), before simulta-
neously adjusting for all indicators within the same group of
factors, and then adjusting for covariates from other groups.
Finally, amongst the majority black women, we estimated
population attributable fractions (PAFs) for advanced stage
BC (stage III/IV v 0/I/II) in public hospital settings, from
logistic regression models regressed on variables that were
signiﬁcant in ordinal models. All analyses were performed
using STATA version 14.2. All p values are two-sided.
Results
A total of 1795 women with BC were included with nonmiss-
ing stage information: 503 (28%) from Namibia; 399 (22%)
from Uganda; 380 (21%) from SA; 371 (21%) from Nigeria
and 142 (8%) from Zambia (Table 1). Hereafter, sample-wide
descriptions and associations are provided in tables, and
where setting-speciﬁc information adds extra insight—this is
provided in the text. At diagnosis, approximately half of
women were premenopausal, half were married and half had
attended secondary education or higher. In total, 178 (10%)
were HIV positive, predominantly women from Namibia
(11% HIV-prevalence), SA (14%) and Uganda (10%). Of the
1415 non-SA women, 169 (12%) had had a recent pregnancy.
From the 945 tumors examined to date, most were ER/
PR1HER22 (57%), 19% were ER/PR1HER21 and 17%
were triple negative. Overall, 1091 women (61%) were diag-
nosed at advanced stage (stage III or IV), of which 15% were
stage IV with lung and liver being the most common meta-
static sites. Among stage 0–II cancers, stages IIA and IIB pre-
dominated; in situ and stage I, that is, tumors <2 cm were
rare (7% overall). The most common symptoms reported by
women (not mutually exclusive) were a lump or thickening
of the breast (87%) followed by pain (26%), and swelling or
lump in the armpit (15%, data not shown).
Ethnic group, country and age at diagnosis
The lowest proportions of advanced stage cancer occurred in
non-black women in Namibia (25%) and in SA (30%), and
the highest in women recruited at the private clinic in Nige-
ria (85%), followed by public hospital patients in Nigeria
(71%), in Namibian black women (64%) and Ugandan
women (64%) (Table 1). Consequently, among core variables,
being black as opposed to non-black emerged as the strongest
determinant of more advanced stage (OR 4.00), which was
partly but not fully explained by woman-level and referral
factors (OR5 2.56; 95% CI 1.69–3.86) (Table 2). This associ-
ation arises from lower stage in the multi-racial populations
in Namibia (where 13% were white and 7% mixed-ancestry)
and SA (5% mixed-ancestry), and was stronger in older than
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Table 2. Associations between woman-level factors, referral indicators and symptom duration with advanced stage at breast cancer diagno-
sis, ABC-DO cohort
Variable Adjustmentfi Core1, n51795
Core11woman-level2
n51669
Core11woman21
referral31 symptom
duration n51594
Category# OR 95% CI OR 95% CI OR 95% CI
Core
Country South Africa 1
Namibia 1.43 1.11–1.83 1.39 1.01–1.92 1.22 0.86–1.73
Nigeria – public 1.73 1.30–2.29 1.76 1.23–2.53 2.41 1.54–3.78
Nigeria – private clinic 2.68 1.68–4.26 3.04 1.81–5.11 4.47 2.46–8.11
Uganda 1.55 1.18–2.03 1.27 0.86–1.87 1.02 0.67–1.54
Zambia 1.21 0.85–1.72 1.18 0.79–1.79 1.22 0.77–1.92
Ethnicity Non-black 1
Black 4.00 2.79–5.74 2.67 1.79–3.97 2.56 1.69–3.86
Age 601 years 1
at diagnosis 50–59 0.98 0.77–1.25 1.14 0.88–1.49 1.12 0.86–1.47
40–49 1.16 0.91–1.47 1.40 1.07–1.83 1.36 1.03–1.80
<40 1.25 0.97–1.61 1.58 1.17–2.13 1.48 1.08–2.03
Woman-level
Marital status Married 1
Not married 1.19 0.99–1.44 1.11 0.91–1.35 1.03 0.84–1.27
Education Secondary 1
<Secondary 1.75 1.42–2.16 1.32 1.04–1.69 1.27 0.98–1.63
Employment Skilled 1
Unskilled 1.77 1.43–2.20 1.38 1.08–1.77 1.34 1.03–1.73
n/a 1.49 1.14–1.94 1.10 0.81–1.49 1.10 0.80–1.51
SEP Continuous score 0.88 0.84–0.92 0.95 0.90–1.01 0.98 0.92–1.04
Ever heard Yes 1
of BC No/unsure 1.64 1.31–2.06 1.24 0.96–1.59 1.26 0.97–1.63
BC knowledge Continuous score 0.77 0.70–0.85 0.83 0.74–0.92 0.86 0.77–0.96
Adjustments as above
Symptom <3 1 1 1
duration 3 to <6 1.47 1.13–1.93 1.36 1.03–1.80 1.33 1.00–1.77
(months) 6 to <12 1.91 1.45–2.52 1.72 1.29–2.29 1.65 1.24–2.20
121 2.47 1.93–3.15 2.15 1.66–2.77 2.03 1.56–2.63
Referral-level
Adjustmentfi
Category# Core1
Core11 referral-level3
n51725
Core11woman21
referral31 symptom duration
n51594
No. contacts 1 1
with care 2 1.43 1.00–2.03 1.39 0.98–1.98 1.35 0.93–1.95
providers 3 1.97 1.34–2.89 1.87 1.27–2.74 1.85 1.23–2.77
4 1.97 1.31–3.05 1.92 1.25–2.93 1.98 1.26–3.10
51 2.41 1.58–3.68 2.32 1.52–3.55 2.04 1.30–3.20
Residence Urban 1
Rural 1.44 1.19–1.73 1.37 1.13–1.67 1.07 0.85–1.34
Abbreviations: BC: breast cancer; CI: confidence interval; n/a: not applicable; OR: ordinal odds ratio; SEP: socio-economic position.
1Basic model: Adjusted for age at diagnosis (<40, 40–49, 50–59, 60 years), country and black versus non-black ethnicity, estimated by ordinal
logistic regression on stage 0, I, IIA, IIB, IIIA, IIIB, IIIC and IV.
2Woman-level factors are marital status, education, employment, socioeconomic position, BC awareness and knowledge.
3Referral factors are place of residence, number of contacts with providers.
younger women (p interaction 0.006, not in tables), reﬂecting
a greater excess of advanced stage disease in black than non-
black women over age 50 (61% vs 20%) than under (67% vs
40%). Country-speciﬁc ethnic differences were also examined,
but were generally underpowered. Nevertheless, in Namibia,
compared to the majority Ovambo women (29% of the sam-
ple), Nama (8%, OR 2.0 (1.0–4.0)) and Angolan (9%, OR 1.7
(1.0–3.1)) women had advanced stage, whilst Damara (11%),
Herero (10%) and Kavango (5%) had raised, albeit not statis-
tically signiﬁcant, ORs of 1.3 to 1.6 (not shown). All settings,
except Zambia, had a more advanced stage at BC diagnosis
than SA, including after taking age and ethnic group into
account. The increase in odds of more advanced BC in
Namibia and Uganda, compared to SA, were fully attenuated
upon adjustment for referral-related, symptom time and
woman-level factors (Table 2). In contrast, compared to SA,
advanced stage at diagnosis in the Nigerian settings could
not be explained by woman-level or reported symptom dura-
tion. Younger age at diagnosis was not associated with more
advanced stage in core models but became signiﬁcant when
adjusted for women-level factors (OR 1.58 for <40 years:
Table 2); the magnitude of this association increased further
upon adjustment for women-level plus biological variables in
the subset with these available (OR 2.02 for <40 years:
Table 3).
Woman-level factors
Lower SEP and lower general educational level were associ-
ated with more advanced stage, as indicated by not having
secondary education (OR 1.75) and holding an unskilled job
(OR 1.77) (Table2). Another indicator (not in Tables) of
lower education, illiteracy, showed similar ﬁndings: in the
one in ﬁve women who were illiterate in both their mother
tongue and English, 76% had advanced stage compared to
60% of literate women. These associations remained after
adjusting for BC-awareness indicators, which were themselves
independently predictive of more advanced stage: never hav-
ing heard of BC (OR 1.64) and poor knowledge of the dis-
ease (OR 0.77 per unit increase in knowledge score).
Similarly, in non-SA sites, not knowing that BC is curable
was also associated with advanced stage (OR 1.27 (1.02–
1.59), not in Tables). These associations were all attenuated
upon adjustment for referral-related factors, especially symp-
tom duration, showing that their associations arise, at least
partially, through a delay in time-to-diagnosis pathway. No
associations were found between stage and parity or marital
status at the time of diagnosis.
Further analyses were conducted to investigate why
woman-level factors were not fully attenuated when adjusting
for symptom duration. Differences persisted when adjustment
for time was continuous as opposed to categorical. Addition-
ally, within each delay stratum, mean tumor size was smaller
among the more educated women (e.g., for symptom dura-
tion of <3 months: 52 mm; 121 months: 65 mm) than
among their less educated counterparts (<3 months: 55 mm;
121 months: 69 mm). Similarly results held for indicators of
poor BC awareness (not shown). Together these ﬁndings sug-
gest that the length of women’s prerecognition intervals may
also have been inversely associated with their educational
level and BC awareness.
Symptom duration and referral factors
The distribution of symptom duration for each setting, over-
all and by advanced stage is shown in Figure 1. The symp-
tom duration was, as expected, strongly associated with more
advanced stage (OR 2.5 for 12 vs <3 month symptom
duration) and was not majorly attenuated upon adjustment
for any factors (Table 2). More prediagnostic contacts with
health care providers or living in rural areas were associated
with longer duration of symptoms (e.g., 18% of women with
one contact reported 12 months with symptoms, vs 45% of
women with 5 contacts, and 30% of urban vs. 37% of
rural-residing women), thus these factors were also associated
with advanced stage, but residential setting was fully attenu-
ated upon adjustment for time with symptoms.
Adjusting for the biological factors listed in Table 3,
within the subset of participants for whom such data were
available, minimally affected the woman-level, referral and
delay associations described above. In particular, the
advanced stage associations with having less than secondary
education (OR 1.57 (1.06–2.31), being in unskilled employ-
ment (OR 1.62 (1.09–2.39) having more BC knowledge (OR
0.79 (0.67–0.92), and having a delay time longer than 3
months (3–<6 months 1.45 (0.96–2.19); 6–<12 months OR
2.21 (1.40–3.51); 121 months OR 2.61 (1.77–3.84)),
remained signiﬁcant, and were in fact even stronger in the
biological subset of women (not in Tables).
Biological factors
Associations between biological factors and more advanced
stage diagnosis are provided in Table 3, based on available
data primarily from Namibia and SA. Compared to those
with well differentiated tumors, women with moderately (OR
1.7) or poorly differentiated (OR 2.1) tumors were more
likely to be diagnosed at a more advanced stage, and this
strong association was, as expected, not confounded by
woman-level or referral factors. Black women still had
advanced stage at diagnosis, compared with non-black
women, after adjusting for both woman-level, and referral
indicators (Table 2) as well as tumor characteristics (Table
3). In this study, there was no suggestion of any association
between HIV status, having other comorbidities or high BMI
with advanced stage. Having had a recent pregnancy within 3
years was independently associated with more advanced stage
at diagnosis in the core model (OR 1.65; 1.15–2.37) and after
adjustment for woman-level and referral factors. Recent preg-
nancy tended to occur in younger women: with little
between-country variation; 30% of women under age 45 were
within 3 years of pregnancy, of which 13% were currently
pregnant, 18% within 1 year, 33% 1 to 1.9 years, and 36% 2
Table 3. Associations between biological factors and advanced stage diagnosis of breast cancer in the ABC-DO cohort
Variable Adjustmentfi
Core model1
n5869
Core11 all
biological n5869
Core11 biological
1woman-level2
n5792
Core11 biological
1 woman2
1 referral31
symptom duration
n5734
Category# OR1 95% CI OR2 95% CI OR3 95% CI OR5 95% CI
Core
Country South Africa 1
Namibia 1.34 1.02–1.78 1.43 1.04–1.97 1.37 0.92–2.06 1.17 0.75–1.82
Nigeria—public 1.06 0.55–2.03 1.19 0.57–2.49 1.59 0.71–3.58 1.65 0.67–4.11
Uganda 0.98 0.53–1.84 1.09 0.55–2.16 1.23 0.56–2.70 1.08 0.47–2.52
Zambia 0.80 0.43–1.50 0.81 0.42–1.54 0.93 0.47–1.87 0.69 0.32–1.47
Ethnicity Non-black 1
black 5.33 3.55–8.01 5.15 3.41–7.77 3.16 1.99–5.01 3.15 1.94–5.10
Age 601 years 1
at diagnosis 50–59 1.08 0.77–1.52 1.10 0.78–1.57 1.40 0.95–2.05 1.39 0.93–2.07
40–49 1.36 0.97–1.90 1.40 0.97–2.02 1.90 1.25–2.89 1.84 1.18–2.87
<40 1.34 0.92–1.94 1.40 0.93–2.10 2.02 1.26–3.23 2.07 1.25–3.42
Biological
HIV Negative/NK 1
Positive 0.97 0.65–1.44 0.94 0.63–1.41 0.88 0.56–1.38 1.03 0.63–1.67
Other No 1
comorbidity Yes 1.02 0.77–1.34 1.02 0.77–1.36 1.02 0.75–1.39 1.00 0.73–1.38
BMI <18.5 1.53 0.86–2.72 1.54 0.87–2.72 0.98 0.53–1.79 0.90 0.47–1.69
(kg/m2) 18.5–<25 1
25–<30 1.05 0.74–1.48 1.04 0.74–1.47 1.06 0.73–1.53 1.09 0.75–1.61
301 1.03 0.75-1.42 0.98 0.72–1.38 1.06 0.74–1.52 1.13 0.77–1.66
Subtype ER/PR1HER2- 1
ER/PR1HER21 0.93 0.67–1.03 0.91 0.65–1.28 0.86 0.60–1.23 0.86 0.58–1.25
HER2-enriched 1.24 0.75–2.06 1.27 0.77–2.12 1.40 0.82–2.38 1.62 0.93–2.80
Triple negative 1.34 0.95–1.90 1.29 0.90–1.85 1.15 0.77–1.67 1.14 0.76–1.71
Grade Well 1
Moderately 1.51 0.96–2.39 1.53 0.96–2.41 1.76 1.09–2.85 1.65 1.01–2.72
Poorly 1.69 1.04–2.74 1.63 1.00–2.67 1.92 1.15–3.21 2.11 1.23–3.60
Unknown 1.29 0.79–2.11 1.24 0.76–2.05 1.30 0.77–2.17 1.43 0.84–2.44
Morphology Ductal 1
Other 1.02 0.74–1.41 1.10 0.79–1.53 1.00 0.70–1.43 0.89 0.61–1.30
Recent pregnancy4 n5540 n5450 n5444 n5435
>3 years 1
3 years 1.65 1.15–2.37 1.58 1.05–2.39 1.88 1.21–2.91 2.00 1.27–3.15
Abbreviations: BMI: body mass index; CI: confidence interval; ER: oestrogen receptor; HER2: human epidermal growth factor receptor 2; HIV: human
immunodeficiency virus; NK: not known; OR: ordinal odds ratio; PR: progesterone receptor; SEP: socio-economic position.
1Basic model: Adjusted for age at diagnosis (<40, 40–49, 50–59, 60 years), country (SA n5 300; Namibia n5460; Uganda n5 42; Zambia
n535; Nigeria n532, Nigeria private not included) and black versus non-black ethnicity, estimated by ordinal logistic regression on stage 0–I,
IIA–IIB, IIIA–IIIC, IV.
2Woman level factors are marital status, education, employment, socioeconomic position, BC awareness and knowledge.
3Referral factors are place of residence, number of contacts with providers.
4Model excludes South Africa and women over 45 years, is adjusted for age as continuous variable and uses all variables in table except tumor
subtype.
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to 2.9 years since last pregnancy. For women having had a
pregnancy within 1 year the association was not signiﬁcant
(core model OR 1.39; 0.83–2.34, not in Tables). There was
some evidence that younger women were at increased odds
of being diagnosed at a more advanced stage; however, simi-
lar to the age associations shown in Table 2, these only
became signiﬁcant upon adjustment for woman-level factors
and were not driven my triple negative tumor subtypes.
PAFs
The proportion of BCs (PAFs) in each country that hypo-
thetically would not have been diagnosed at an advanced
stage (stage III/IV) if all women had experienced a time to
diagnosis within 3 months of symptoms, had at least second-
ary education, worked in skilled employment, had heard of
BC and scored the highest on the BC knowledge score was
estimated overall at 42% (95% CI 30–52%), and ranged from
34% in Nigeria to 49% in Uganda. The advanced stage con-
tribution associated with recent pregnancy was estimated at
6% (2–10%) among women 45 years of age, and ranged
from 4% in Uganda to 7% in Namibia and Zambia. The
contribution of tumor aggressiveness was 12% in Namibia
and 13% in SA; these were estimated for the two countries
where receptor status assessment is done routinely by
hypothesizing the scenario whereby all women were diag-
nosed in the favorable categories of having well-differentiated
and non-triple-negative tumors.
Discussion
Main findings
This study identiﬁed key determinants of stage at BC diagno-
sis across ﬁve countries in SSA. Advanced stage (stage III/IV)
at diagnosis constituted the majority of BC in all black popu-
lations but the extent differed between countries, and con-
trasted starkly to a majority stage 0/I/II disease in non-black
women in Namibia and SA. In addition, younger age and a
recent pregnancy were independently associated with more
advanced stage, as were several amenable factors: low educa-
tion and socioeconomic position, working in unskilled
employment, and poor BC awareness. These factors were
mediated at least in part through a time-to-diagnosis path-
way, as one-third of SA black women, half of Nigerian and
Figure 1. Symptom duration: self-reported time from symptom to diagnosis. (a) Distribution of time overall for each country/setting. (B) Dis-
tribution of time by advanced stage diagnosis for each country/setting. [Color figure can be viewed at wileyonlinelibrary.com]
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Namibian women and three-quarters of Ugandan women
reported having had symptoms for over 6 months, making
this the largest contributor to advanced stage at diagnosis.
Higher grade and triple-negative tumors also tended to be
more advanced stage tumors.
Comparisons with other studies
Many of these ﬁndings are consistent with previous work in
SSA. Low levels of education have, not surprisingly, been
found to be associated with advanced stage BC in many stud-
ies in the region.24–26 Long delays between ﬁrst symptom rec-
ognition and diagnosis are also consistent with previous SSA
research,24 and were associated with more visits to health
care provider facilities.25 Reducing delays to three months is
a reasonable target in SSA, as it is difﬁcult to show any wors-
ening of outcome when treatment is initiated after that time;
delays longer than one year should be considered extreme in
any system. Previous studies have found that women who
were not married at the time of BC diagnosis were more
likely to be advanced stage or have long delays before seeking
help24,26; in this study, this association was accounted for by
their lower SEP. Overweight and obesity did not emerge as
being related to more advanced stage, in contrast to other
Western settings,27,28 even though the prevalence of over-
weight and obesity was relatively high in the ABC-DO study
(60%).
As expected, there was an association between higher
grade tumors and more advanced stage; however, no associa-
tion emerged for tumor morphological subtype. Several stud-
ies have highlighted more aggressive BC subtypes (e.g. triple
negative tumors) in SSA,29,30 but a recent systematic review
and meta-analysis demonstrated a predominance of better
prognosis oestrogen-receptor (ER)-positive tumors in
SSA.31,32 The ABC-DO ﬁndings conﬁrm that triple negative
tumors are diagnosed later, but they made up less than one-
ﬁfth of tumors, thus of the factors studied, nonbiological fac-
tors were the main drivers of advanced stage BC. Biological
factors were limited, however, both in sample size and to
immunohistochemical markers, thus molecular studies of BC
in SSA are needed and may identify stronger additional driv-
ers of diagnostic stage. Further, although the study popula-
tion was primarily black, lower stage in the minority non-
black women in Namibia and SA, who were diagnosed in the
same settings as their black counterparts, highlights the pros-
pect for downstaging. While the ethnic differential in
advanced tumors is likely to partially be due to less aggressive
tumors in non-black women, it is likely additionally driven
by a complex combination of BC awareness, education, cul-
ture, ﬁnancial means and privilege.25,32–34
Strengths and limitations
This study was conducted primarily in tertiary hospital set-
tings, with the latter being often the only cancer treatment
centers in the country. Although participation rates were very
high (99%), the cohort may not be representative of all BC
patients as women who never seek health care or are never
referred to a diagnostic hospital will not be represented. For
example, during the study conduct, strike action from differ-
ent groups of health professionals severely interrupted diag-
nosis during prolonged periods, yet a catch-up was not
observed; women may have travelled abroad or sought treat-
ment in the rapidly expanding private sector. The study
beneﬁtted from highly complete questionnaire data, aided by
m-Health implementation (described in detail in the ABC-
DO study protocol).15 However, symptom recognition and,
therefore, estimations of delays were dependent on patient
recollection, and therefore may not be entirely accurate.
Information on stage and other tumor characteristics were
extracted from medical records and the quality may be vari-
able. Furthermore information on receptor status was not
available for most women outside Namibia and SA, which is
a problem inherent to SSA that prevents women from
beneﬁtting from optimal treatments for their type of tumor.
Implications
The ﬁndings help to identify which groups of women are
vulnerable to advanced stage disease and strategies to
improve early presentation and diagnosis. The breast cancer
patients identiﬁed in this study as more likely to be diag-
nosed with advanced disease, such as black women, women
with low levels of literacy and education, and working in
unskilled employment, are not women of privilege. The fact
that the associations found for woman-level factors such as
working in unskilled employment remained after accounting
for recognized delay time, suggest that they may be also
reﬂecting the ‘uncaptured’ time from detectable symptoms to
symptom recognition. Help seeking behavior depends heavily
on the way a woman views herself, her status, and her roles
within her community (as wife, mother, daughter, etc.), and
looking at the wider scope, empowerment also plays a key
role in SSA BC disparities.34,35 The current study was only
able to capture part of the pre-diagnostic journey, that is, it
was unable to measure the symptom-onset to symptom rec-
ognition interval.36 A common theme in symptom appraisal
models is that, for a bodily change or symptom, to be
detected it must be of sufﬁcient signiﬁcance,14 meaning the
likelihood of symptoms going unnoticed is greater among
those with external competing demands,37,38 and such kinds
of demands have been associated with lower socioeconomic
demographics.39
Greater BC awareness was associated with lower stage dis-
ease, independently of educational level. This ﬁnding suggests
that although stage migration in SSA may be achieved in the
long-term through improvements in the general education
level of women, it raises the prospect that it may also beneﬁt
in the short-term from speciﬁcally-tailored BC awareness
interventions, such as community education on BC symp-
toms, breast self-examination, where to seek help and of the
potential to cure BC. Of relevance in this context is the fact
that in this population overall, one in ﬁve women were
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illiterate, therefore print materials would not be solely effec-
tive and awareness campaigns via the radio, in markets,
churches, schools and community places, are needed to be
inclusive.40,41 Such activities have increased in SSA in recent
years, especially by cancer associations, including of the
important efforts of cancer survivors to tackle stigma. Meth-
ods currently seen across SSA include education using pam-
phlets, cancer walks, wear pink days and advocacy. In
addition to increasing awareness in communities, awareness
in health professionals has also been tackled in successful
down-staging interventions.42,43 Clinical breast examination
has been associated with shorter delays to diagnosis and may
also be of value as an educational tool for breast awareness
in resource limited settings.44
More advanced stage at diagnosis in recently pregnant
women has been found internationally,21,45,46 but this study
is the ﬁrst such report from SSA and was consistent across
its countries. It may indicate a common hormonal-driver of
proliferation and more diagnostic challenges within lactating
breasts, or it may simply reﬂect greater time demands of rais-
ing infant children, as the majority were women who had
given birth 2–3 years ago. Under age 45, 30% of women with
a recent or current pregnancy had more advanced BCs and
somewhat surprisingly, this group made up 30% of BC
patients diagnosed under age 45. In this age group, this
group largely reﬂected recent (27% of BCs) rather than cur-
rent pregnancies (3%), as the latter is a similar percentage to
very different settings.47 Thus, although women had their
ﬁrst pregnancies early (median 21 years), the reproductive
period from ﬁrst to last pregnancy was often long. Of the BC
patients, 25% had their last pregnancy at or over 40 years of
age, similar to historical values in western countries.48
Although BC risk is small during/postpregnancy, the contact
with the health system during and postpregnancy offers an
ideal opportunity for educating women on breast health and
women’s cancers both for the near and distant future. Link-
ing BC early detection efforts to reproductive health clinics
would be a sensible targeting educational opportunity,
regardless of the association driver.
Finally, HIV-positive women did not have more advanced
stage at BC diagnosis; nevertheless, their contact with the
health system could also offer an opportunity for earlier diag-
nosis. Ideally being diagnosed HIV positive, or diagnosed
with any comorbidity that requires regular contact with
health professionals, should be associated with a lower stage
diagnosis. Within this study, 89% of HIV positive women
were receiving antiretroviral therapy, and while these women
were diagnosed at earlier stages than their counterparts not
on therapy, they were still later stage than HIV negative
women. Once again this highlights the importance of educa-
tion for both women and health professionals and the oppor-
tunities that arise when they interact.
Conclusion
There is an urgent need to improve breast cancer survival
rates in SSA as the incidence burden increases over the com-
ing decades. Downward stage migration, followed by timely
treatment, is essential to this. This study has identiﬁed groups
of women who are vulnerable to delays in diagnosis, for
whom downward stage migration may be achievable through
a combination of strategies that improve breast cancer aware-
ness and promote timely help-seeking behavior with
improvements in access to health care.
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